Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients

Reuters

Sep 27, 2025

Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients

Immuneering Corporation has announced updated overall survival and safety data from its Phase 2a clinical trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients. The results, based on a cohort of 34 patients with a median follow up of nine months, were first disclosed in a press release on September 24, 2025. The data will be highlighted in a poster presentation at the upcoming Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 and further discussed during a company-hosted conference call and webcast scheduled for September 29, 2025. A webcast replay and related corporate materials will be made available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536057-en) on September 26, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570834033"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570834033\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570834033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-27 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570834033","market":"fut","top_or_hot":-1,"title":"Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immuneering Corporation has announced updated overall survival and safety data from its Phase 2a clinical trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients. The results, based on a cohort of 34 patients with a median follow up of nine months, were first disclosed in a press release on September 24, 2025. The data will be highlighted in a poster presentation at the upcoming Pancreatic Cancer Action Network (PanCAN) Scientific <a href=\"https://laohu8.com/S/SMMT\">Summit</a> 2025 and further discussed during a company-hosted conference call and webcast scheduled for September 29, 2025. A webcast replay and related corporate materials will be made available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536057-en) on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-27 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Immuneering Corporation has announced updated overall survival and safety data from its Phase 2a clinical trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients. The results, based on a cohort of 34 patients with a median follow up of nine months, were first disclosed in a press release on September 24, 2025. The data will be highlighted in a poster presentation at the upcoming Pancreatic Cancer Action Network (PanCAN) Scientific <a href=\"https://laohu8.com/S/SMMT\">Summit</a> 2025 and further discussed during a company-hosted conference call and webcast scheduled for September 29, 2025. A webcast replay and related corporate materials will be made available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536057-en) on September 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDLb3Qf86:1","article_id":"2570834033","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570834033","pubTimestamp":1758916869,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients. Immuneering Corporation has announced updated overall survival and safety data from its Phase 2a clinical trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients. The results, based on a cohort of 34 patients with a median follow up of nine months, were first disclosed in a press release on September 24, 2025. The data will be highlighted in a poster presentation at the upcoming Pancreatic Cancer Action Network  Scientific Summit 2025 and further discussed during a company-hosted conference call and webcast scheduled for September 29, 2025. A webcast replay and related corporate materials will be made available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IMRX":"Immuneering Corp","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4563":"昨日强势股"},"translate_title":"Immuneering公布Atebimetinib+mGnP一线胰腺癌患者2a期试验有希望的总生存数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"IMRX":0.9},"content_text":"Immuneering Announces Promising Overall Survival Data from Phase 2a Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients\n    \n\n        Immuneering Corporation has announced updated overall survival and safety data from its Phase 2a clinical trial evaluating atebimetinib in combination with mGnP in first-line pancreatic cancer patients. The results, based on a cohort of 34 patients with a median follow up of nine months, were first disclosed in a press release on September 24, 2025. The data will be highlighted in a poster presentation at the upcoming Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 and further discussed during a company-hosted conference call and webcast scheduled for September 29, 2025. A webcast replay and related corporate materials will be made available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536057-en) on September 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}